Intellia Therapeutics Ownership | Who Owns Intellia Therapeutics?
Intellia Therapeutics Ownership Summary
Intellia Therapeutics is owned by 3.68% institutional investors, 4.96% insiders, and 91.36% retail investors. Ark investment management is the largest institutional shareholder, holding 12.41% of NTLA shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 8.41% of its assets in Intellia Therapeutics shares.
NTLA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Intellia Therapeutics | 3.68% | 4.96% | 91.36% |
| Sector | Healthcare Stocks | 279.19% | 10.62% | -189.81% |
| Industry | Biotech Stocks | 63.96% | 10.74% | 25.30% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Ark investment management | 12.54M | 12.41% | $146.17M |
| Blackrock funding, inc. /de | 10.86M | 10.75% | $126.60M |
| Vanguard group | 10.19M | 10.09% | $118.82M |
| Blackrock | 9.60M | 10.05% | $214.79M |
| State street | 4.36M | 4.57% | $97.64M |
| Regeneron pharmaceuticals | 3.70M | 3.67% | $43.18M |
| Nikko asset management americas | 2.99M | 2.96% | $34.89M |
| Sumitomo mitsui trust | 2.99M | 2.96% | $34.89M |
| Morgan stanley | 2.34M | 2.45% | $52.32M |
| Geode capital management | 2.39M | 2.37% | $27.86M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Regeneron pharmaceuticals | 3.70M | 3.94% | $43.18M |
| Discovery value fund | 561.56K | 3.76% | $6.55M |
| Contrarius investment management | 1.92M | 2.68% | $42.87M |
| Himension capital (singapore) pte. | 1.03M | 1.63% | $23.05M |
| Ark investment management | 12.54M | 1.22% | $146.17M |
| Casdin capital | 2.00M | 1.16% | $14.22M |
| Orchard capital management | 170.01K | 1.15% | $3.80M |
| Sphera funds management | 466.08K | 0.98% | $5.43M |
| Second line capital | 131.12K | 0.41% | $1.53M |
| Nikko asset management americas | 2.99M | 0.38% | $34.89M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Regeneron pharmaceuticals | 3.70M | 3.94% | 3.70M |
| Balyasny asset management | 2.31M | 0.04% | 1.56M |
| Ubs group | 1.74M | 0.00% | 1.46M |
| Blackrock funding, inc. /de | 10.86M | 0.00% | 1.08M |
| Voloridge investment management | 1.53M | 0.06% | 1.06M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Deep track capital, lp | - | - | -4.95M |
| Federated hermes | 3.85K | 0.00% | -2.74M |
| Alliancebernstein | 265.32K | 0.00% | -1.93M |
| Pictet asset management sa | - | - | -1.39M |
| Rokos capital management llp | - | - | -1.14M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Regeneron pharmaceuticals | 3.70M | 3.94% | 3.70M | $43.18M |
| Raymond james financial | 411.08K | 0.00% | 411.08K | $4.79M |
| Aptus capital advisors | 139.28K | 0.02% | 139.28K | $1.62M |
| Second line capital | 131.12K | 0.41% | 131.12K | $1.53M |
| Aqr capital management | 35.76K | 0.00% | 35.76K | $416.93K |
Sold Out
| Holder | Change |
|---|---|
| Global financial private client | -1.00 |
| Dinuzzo private wealth | -1.00 |
| Richard w. paul & associates | -2.00 |
| Jfs wealth advisors | -2.00 |
| Baldwin brothers llc/ma | -4.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 6 | -98.05% | 3,804,135 | -96.17% | 3 | 0.04% | 3 | -98.41% | 1 | -98.55% |
| Dec 31, 2024 | 286 | -2.39% | 92,252,291 | -1.01% | 91 | 1.07% | 178 | 17.11% | 61 | -27.38% |
| Sep 30, 2024 | 290 | -5.54% | 93,104,860 | 3.35% | 92 | 1.07% | 150 | -7.41% | 84 | -4.55% |
| Jun 30, 2024 | 302 | 0.67% | 90,028,919 | -0.69% | 94 | 1.05% | 160 | 5.26% | 86 | -2.27% |
| Mar 31, 2024 | 300 | -2.28% | 90,656,601 | 6.41% | 94 | 1.03% | 152 | -11.11% | 88 | 10.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| ARK Disruptive Innovation Full Composite | 8.70M | 8.41% | 81.62K |
| ARK Innovation ETF | 8.52M | 8.23% | -12.77K |
| American Funds SMALLCAP World A | 3.78M | 3.65% | 3.78M |
| Vanguard Total Stock Mkt Idx Inv | 3.24M | 3.12% | 104.20K |
| Vanguard US Total Market Shares ETF | 3.17M | 3.06% | 299.88K |
| ARK Genomic Revolution | 3.10M | 2.99% | 235.36K |
| ARK Genomic Revolution ETF | 2.86M | 2.76% | - |
| iShares Russell 2000 ETF | 2.61M | 2.52% | 1.28K |
| Vanguard Small Cap Index | 2.56M | 2.47% | 20.66K |
| SPDR® S&P Biotech ETF | 2.03M | 1.96% | 2.63K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Apr 29, 2025 | Bhanji Muna | - | Sell | $2.25K |
| Mar 04, 2025 | Clark Eliana | EVP, Chief Technical Officer | Sell | $6.10K |
| Mar 04, 2025 | BASTA JAMES | EVP, General Counsel | Sell | $23.12K |
| Jan 29, 2025 | Bhanji Muna | - | Sell | $2.64K |
| Jan 03, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sell | $16.71K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | - | 1 |
| 2025 Q1 | - | 11 |
| 2024 Q4 | - | 1 |
| 2024 Q3 | - | 1 |
| 2024 Q2 | - | 1 |
NTLA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools